KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Restructuring Costs (2016 - 2025)

Eli Lilly's Restructuring Costs history spans 17 years, with the latest figure at $84.1 million for Q4 2025.

  • For Q4 2025, Restructuring Costs fell 75.58% year-over-year to $84.1 million; the TTM value through Dec 2025 reached $484.0 million, down 43.79%, while the annual FY2025 figure was $484.0 million, 43.79% down from the prior year.
  • Restructuring Costs reached $84.1 million in Q4 2025 per LLY's latest filing, down from $364.9 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $435.0 million in Q2 2024 to a low of $35.0 million in Q1 2025.
  • Average Restructuring Costs over 5 years is $179.4 million, with a median of $104.5 million recorded in 2021.
  • Peak YoY movement for Restructuring Costs: soared 447.18% in 2021, then tumbled 75.58% in 2025.
  • A 5-year view of Restructuring Costs shows it stood at $104.5 million in 2021, then tumbled by 63.54% to $38.1 million in 2022, then soared by 78.48% to $68.0 million in 2023, then soared by 406.47% to $344.4 million in 2024, then crashed by 75.58% to $84.1 million in 2025.
  • Per Business Quant, the three most recent readings for LLY's Restructuring Costs are $84.1 million (Q4 2025), $364.9 million (Q3 2025), and $35.0 million (Q1 2025).